| Business: |
We are an investment holding company; through our subsidiary, we assemble and commercialize advanced miscroscopy-related solutions, technologies and products. (Incorporated in the Cayman Islands)
Using its patented microsphere-assisted technology, the company can significantly increase the magnification of an existing traditional optical microscope compared to its competitors, hence allowing our clients to see beyond the optical limit in an effective manner. Currently, it is the only commercially available advanced optical microscope that can see below the 200nm optical limit, within a commercially viable working distance.
Our business is primarily involved in the assembling and commercialization of advanced microscopy-related solutions, technologies and products tailored for precision measurement and magnification purposes. Our range of product includes optical microscopy solutions, featuring:
|
i)
|
Super-resolution imagers capable of achieving imaging down to 137nm;
|
|
|
|
|
ii)
|
Specialized microscopes designed to meet the diverse needs of various industries; and
|
|
|
|
|
iii)
|
Three-dimensional (“3-D”) real-time image magnifiers for enhanced visualization.
|
Traditional optical microscopes are able to see up to 250nm, while our solution allows users to see up to 137nm. As a result, we believe that this is considered by the optical industry as a super resolution optical microscopy solution.
In addition to our hardware offerings, we currently provide complimentary proprietary software, which is developed in-house. This software includes Artificial Intelligent (“AI”) components that allows our customers to perform recognition patterns for research, quality assurance and quality control (“QA/QC”), as well as diagnostics purposes. The in-house software is meticulously crafted to complement our product line ensuring seamless integration and optimized performance for our customers.
For the financial years ended April 30, 2023 and 2024, the provision of microscopy products contributed to 73.9% and 97.6% of our revenue, respectively.
We distribute our microscopy products with software solutions through an extensive network of distributors, primarily in Singapore and expanding across regions such as Southeast Asia and South Asia. Our microscopy solutions accommodate a diverse range of applications enabling us to serve a wide range of customer needs and capitalize on emerging growth opportunities in the region. Our diverse customer base primarily includes industries with usage in fields such as manufacturing, research & development, biomedical, semiconductors, Printed Circuit Board (“PCB”), electronics, precision engineering, injection molding, research, healthcare, QA/QC and diagnostics. Our business strategic focus involves strengthening our market position in Singapore and progressively expanding into the Southeast Asian region.
Note: Net loss and revenue are in U.S. dollars for the fiscal year that ended April 30, 2024.
(Note: Phaos Technology (Cayman) Holdings Ltd. filed its F-1 and disclosed the terms for its micro-cap IPO – 2.7 million shares at a price range of $4.00 to $5.00 to raise $12.15 million – in an SEC filing dated Jan. 3, 2025.)
|
